AbbVie Inc (ABBV)vsAdagio Medical Holdings, Inc Common Stock (ADGM)
ABBV
AbbVie Inc
$211.32
+3.64%
HEALTHCARE · Cap: $360.63B
ADGM
Adagio Medical Holdings, Inc Common Stock
$1.05
-3.67%
HEALTHCARE · Cap: $23.32M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 44642237% more annual revenue ($61.16B vs $137,000). ABBV leads profitability with a 6.9% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
ADGM
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-29.3%
Fair Value
$163.42
Current Price
$211.32
$47.90 premium
Intrinsic value data unavailable for ADGM.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 34.1%
Conservative balance sheet, low leverage
Generating 4.9B in free cash flow
Revenue surging 75.6% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Areas to Watch
6.9% margin — thin
Premium valuation, high expectations priced in
Earnings declined 88.7%
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. PEG of 0.48 suggests the stock is reasonably priced for its growth.
Bull Case : ADGM
The strongest argument for ADGM centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 75.6% demonstrates continued momentum.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 100.0x leaves little room for execution misses.
Bear Case : ADGM
The primary concerns for ADGM are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a value stock while ADGM is a hypergrowth play — different risk/reward profiles.
ABBV carries more volatility with a beta of 0.36 — expect wider price swings.
ADGM is growing revenue faster at 75.6% — sustainability is the question.
ABBV generates stronger free cash flow (4.9B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 37/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Adagio Medical Holdings, Inc Common Stock
HEALTHCARE · MEDICAL DEVICES · USA
Adagio Medical Holdings, Inc. is a cutting-edge biotechnology company focused on developing advanced medical technologies for the treatment of cardiac arrhythmias. By leveraging its proprietary platform, Adagio is pioneering innovative targeted ablation techniques that fulfill significant gaps in the electrophysiology market. With a promising product pipeline and an experienced leadership team, the company offers a compelling investment opportunity for institutional investors seeking to participate in the rapidly evolving healthcare landscape and enhance patient care in the cardiac domain.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?